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Osteoporosis(ECLIPSE study) for 2164 clinically stable COPD subjects, 337 smokers and 245 non-smokers
with normal lung function.
COPD patients had a higher prevalence of osteoporosis, anxiety/panic attacks, heart
trouble, heart attack, and heart failure, than smokers or nonsmokers. Heart failure (Hazard
Ratio [HR] 1.9, 95% Confidence Interval [CI] 1.3e2.9), ischemic heart disease (HR 1.5, 95% CI
1.1e2.0), heart disease (HR 1.5, 95% CI 1.2e2.0), and diabetes (HR 1.7, 95% CI 1.2e2.4) had
increased odds of mortality when coexistent with COPD. Multiple comorbidities had accumula-
tive effect on mortality. COPD and cardiovascular disease was associated with poorer quality of
life, higher MRC dyspnea scores, reduced 6MWD, higher BODE index scores. Osteoporosis, hy-
pertension and diabetes were associated with higher MRC dyspnea scores and reduced 6MWD.
Higher blood concentrations of fibrinogen, IL-6 and IL-8 levels occurred in those with heart dis-
ease.
Comorbidity is associated with poor clinical outcomes in COPD. The comorbidities of heart
disease, hypertension and diabetes are associated with increased systemic inflammation.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
COPD is a preventable and treatable condition1 which is
often associated with comorbid conditions such as car-
diovascular2e4 and cerebrovascular disease,5 osteoporosis,6
depression,7 lung cancer8 and diabetes.9 Population studies
investigating the prevalence of cardiovascular disease,
stroke, diabetes and hypertension in the COPD population
conclude that these conditions are more likely to co-exist
with COPD than in the general population.10 However, the
prevalence of individual comorbidities varies widely be-
tween different studies.
Comorbidities in COPD patients have a direct impact on
the clinical course of the disease since they are associated
with an increased risk of hospitalization and death10e12 as
well as with an increased cost of care in COPD13,14 but
despite this they are often under-diagnosed and under-
treated.15,16
Whether or not comorbidities are pathogenically linked
to the pulmonary abnormalities that characterize COPD or
merely represent the co-existence of several, prevalent,
age-related diseases is unclear. Since most comorbidities
are characterized by low-grade chronic systemic inflam-
mation, it has been hypothesized that chronic systemic
inflammation may be a key factor linking COPD with its
comorbidities.17,18 ECLIPSE is a large observational cohort
study of subjects with COPD and smokers and non-smokers
with normal lung function, conducted at 46 centers in 12
countries that aimed to define distinct COPD phenotypes
and identify biomarkers and/or genetic parameters that
predict disease progression.19,20 ECLIPSE therefore pro-
vides the opportunity to investigate in more detail the role
of comorbidities in COPD. Using data from the ECLIPSE
cohort we aimed (i) to establish the type and the propor-
tion of patients with comorbidities in this COPD cohort
compared to smokers and non-smokers with normal lung
function; and (ii) to explore the characteristics of COPD
patients with these comorbidities in relation to systemic
inflammation and clinical outcome measures. Our hy-
pothesis was that comorbidities would be associated with
poor clinical outcomes and increased systemic
inflammation.Methods
Study design
The study design of ECLIPSE (Clinicaltrials.gov identifier
NCT00292552; GSK study code SCO104960) has been pub-
lished previously.19 In brief, ECLIPSE is an observational,
longitudinal study in which, after the baseline visit, par-
ticipants were evaluated at 3 months, 6 months and then
every 6 months for 3 years. Results presented here repre-
sent the cross-sectional analysis of the data obtained at
baseline and after 1060 days follow up.Study cohorts
2164 COPD patients (GOLD stage IIeIV), 337 smokers
(smokers) and 245 non-smokers (non-smokers) with normal
lung function were included in ECLIPSE (Table 1). Inclusion
criteria were19: COPD patients: (1) male/female subjects
aged 40e75 years; (2) baseline post-bronchodilator FEV1
<80% of the reference value and FEV1/FVC 0.7; and, (3)
current or ex-smokers with a smoking history of 10 pack
years. Smokers: (1) male/female subjects aged 40e75 years
who were free from significant lung disease as determined
by history, physical examination and screening investiga-
tion; (2) baseline post-bronchodilator FEV1 > 85% of the
reference value and FEV1/FVC >0.7; and (3) current or ex-
smokers with a smoking history of 10 pack years. Non-
smokers: (1) male/female subjects aged 40e75 years who
were free from significant lung disease as determined by
history, physical examination and screening investigation;
(2) baseline post-bronchodilator FEV1 >85% of the refer-
ence value and FEV1/FVC >0.7; and (3) smoking history of
<1 pack year. All participants signed and dated their
written informed consent prior to participation (which had
been approved by the ethics committees of all participating
institutions); all subjects had to have the ability to comply
with the requirements of the protocol and be available for
study visits over 3 years. Key exclusion criteria were the
presence of a respiratory disorder other than COPD. Sub-
jects with comorbidities were not excluded but had to be
Table 1 Baseline characteristics of COPD subjects compared to healthy smoking and non-smoking control subjects. Data are
presented as mean  SD or proportion of the main clinical and functional variables as previously reported.20
COPD (n Z 2164) Smokers (n Z 337) Non-smokers (n Z 245) p Value
Clinical data
Age, years 63.4  7.1a,b,d 55.4  9.0 54.1  9.0 <0.001
Male, % 65 55c 38 <0.001
Pack-years 48.6  27.1a,b,d 31.6  21.5d 0.2  1.1 <0.001
Current Smokers, % 36a,d 61d 0 <0.001
BMI, kg/m2 26.5  5.7b 26.8  4.6c 27.7  5.4 0.002
FFMI, kg/m2 17.2  2.8b 17.1  2.6c 17.2  2.7 0.0.002
mMRC Score 1.7  1.1a,b,d 0.2  0.5 0.1  0.3 <0.001
SGRQ-C total score 50.1  20.3a,b 9.6  12.3c 4.8  6.5 <0.001
FEV1, % predicted 48.3  15.8a,b 108.6  12.0c 114.8  13.9 <0.001
FEV1/FVC, % 44.8  11.6a,b 79.2  5.2 81.1  5.2 <0.001
FEV1 reversibility, % 10.7  13.7a,b 4.5  5.8 2.7  4.5 <0.001
Distance walked (meters) 369  122
BODE index 3.2  2.1
Emphysema, % 17.7  12.3a,b 2.4  3.1c 4.1  4.2 <0.001
Number of exacerbationsz 0.8  1.2a,b 0.0  0.1 0.0  0.0 <0.001
Death during 1060 days follow up, % 10a,b,d <1 <1 <0.001
a p < 0.05 COPD vs. smokers.
b p < 0.05 COPD vs. non-smokers.
c p < 0.01 smokers vs. non-smokers.
d In the year prior to study entry.
1378 J. Miller et al.clinically stable at the time of assessment, in particular
subjects with rheumatoid arthritis and inflammatory bowel
disease that was active at recruitment were excluded.
Patients who had an exacerbation of COPD within 4 weeks
of enrollment were also excluded.19 COPD patients were
recruited from the outpatient clinics of the participating
centers. Smoker and non-smoker controls were recruited
through databases at these sites and other methods (ad-
vertisements in local newspaper and television/radio sta-
tions) as appropriate. Baseline characteristics of the
cohorts have previously been reported.20Measurements
The American Thoracic Society-Division of Lung Diseases
(ATS-DLD-78) questionnaire, the modified Medical Research
Questionnaire (mMRC) and the COPD-specific version of the
St. George’s Respiratory Questionnaire (SGRQ-C) were used
to record clinical data. Exacerbations requiring treatment
with antibiotics, oral corticosteroids and/or hospitalization
(moderate/severe exacerbations) in the year prior to the
study were also recorded. Comorbidities were self-reported
using the ATS-DLD-78 questionnaire. Nutritional status was
assessed by the body mass index (BMI) and fat-free mass
index (FFMI) determined from bioelectrical impedance.
Spirometry and the 6-min walking distance (6MWD) were
performed according to international guidelines.21,22
Spirometric reference values were those of the European
Community for Coal and Steel (ECCS).23 The BODE index
was calculated according to Celli et al.24
All subjects underwent a low-dose computed tomogra-
phy (CT) scan of the chest acquired using multi-detector-
row CT scanners (GE Healthcare or Siemens Healthcare)with a minimum of 4 rows, obtained in the supine position,
at suspended full inspiration, without administration of
intravenous contrast. Exposure settings were 120 kVp and
40 mAs and images were reconstructed using 1.0 mm
(Siemens) or 1.25 mm (GE) contiguous slices and a low
spatial frequency reconstruction algorithm (GE: Standard;
Siemens: b35f). CT scanners were calibrated regularly using
industry and institutional standards. All of the CT scans
were evaluated at the central imaging unit at the University
of British Columbia, Vancouver. Quantitative assessment of
the percentage of low attenuation areas (%LAA), repre-
senting the presence of emphysema, was performed using a
threshold of 950 Hounsfield units (VIDA Diagnostics, Iowa
City, IA, USA).
Peripheral venous blood was collected into Vacutainer
tubes, in the morning, after fasting overnight, at baseline
and at all visits. Circulating white blood cell (WBC) count
was measured at each participating center. Serum was
prepared by centrifugation of whole blood at 1500 g for
10e15 min and plasma (EDTA as the anticoagulant) was
obtained by centrifugation at 2000 g for 10e15 min. Sam-
ples were stored at 80 C until analyzed centrally. IL-6,
IL-8 and TNF-a serum concentrations were determined by
validated immunoassays (SearchLight Array Technology,
Thermo Fisher Scientific, and Rockford, IL, USA). Serum SP-
D was measured using a colorimetric sandwich immuno-
assay method (BioVendor, Heidelberg, Germany). PARC/
CCL-18 levels were measured using a human CCL18/PARC
DuoSet ELISA kit (R&D systems). High-sensitivity C-reactive
protein (hs-CRP) (Roche Diagnostics, Mannheim, Germany)
and fibrinogen (K-ASSAY fibrinogen test, Kamiya Biomedical
Co., Seattle, WA, USA) levels were measured using immu-
noturbidometric assays validated for use with EDTA
plasma.
Figure 1 Percentage of COPD subjects, smokers and non-
smokers with general comorbidities e ***P < 0.001 comparing
COPD with smokers and non-smokers; þþ p < 0.01, þp < 0.05
comparing COPD with control non-smokers (p values adjusted
for age and gender).
Figure 2 Percentage of COPD subjects, smokers and non-
smokers with cardiovascular comorbidities e ***p < 0.01,
**p < 001, *p < 0.05 comparing COPD with control smokers and
non-smokers; þp < 0.05 comparing COPD with smokers (p
values adjusted for age and gender).
Comorbidity, inflammation and outcome in COPD 1379Statistical analysis
Results are shown as mean  SD, median [interquartile
range, IQR], or percentage, as appropriate. Analyses of
variance or van Elteren tests were used to analyze differ-
ences for continuous variables. Differences in categorical
variables were assessed using CochraneManteleHaenszel
tests. P values for comparisons between cohorts (COPD
Subjects, Smoker Controls, and Non-smoker Controls) were
adjusted for age and gender, while p values for comparisons
within COPD subjects were adjusted for age, gender, and
smoking pack year history. Survival curves were con-
structed from Cox proportional hazard models that
included terms for age, gender, and smoking pack year
history. Additionally, hazard ratios (HR) are presented from
the same models. Odds ratios from logistic regression
models that adjusted for age, gender, and smoking pack
year history are also calculated. P values less than 0.05
(two sided) were considered significant. No adjustments for
multiple comparisons were done. All analyses were con-
ducted with SAS Version 9.1 (Cary, NC).
Role of the funding source
The study was sponsored by GlaxoSmithKline. A Steering
Committee and a Scientific Committee comprising in total
ten academics and six representatives of the sponsor
developed the original study design and concept, the plan
for the current analyses, approved the statistical plan, had
full access to the data and was responsible for decisions
with regard to publication. The study sponsor did not place
any restrictions with regard to statements made in the final
paper.
Results
2164 COPD subjects, 337 smokers and 245 non-smokers with
normal lung function controls were recruited as part of the
ECLIPSE study, as previously reported.19,20 Table 1 shows
the baseline characteristics of the COPD subjects compared
with smokers and non-smokers. The smokers were slightly
younger than COPD subjects and had lower pack years
smoking history. The non-smokers had a higher BMI and a
higher FFMI than COPD subjects and the smokers. As ex-
pected, COPD subjects had higher modified MRC dyspnea
scores, and SGRQ-C scores than the smokers or non-
smokers. Six minute walking distance and BODE index
scores were determined for COPD subjects, but not for the
smokers or non e smokers. By definition COPD subjects had
chronic airflow limitation, whereas smokers and non-
smokers had normal spirometry. COPD subjects had signif-
icantly greater %LAA on CT analysis and a significantly
higher mortality during the 1060-day follow up period
(Table 1).
Proportion and types of comorbidities in the COPD
cohort
Fig. 1 shows the prevalence of general comorbidities.
Compared with smokers and non-smokers, COPD subjectshad a higher prevalence of self-reported osteoporosis,
anxiety/panic attacks, peptic ulcer disease, depression
requiring treatment, and diabetes, although the latter did
not reach statistical significance after adjustment for age
and gender. Osteoarthritis, inflammatory bowel disorder
and rheumatoid arthritis were not more prevalent in COPD
subjects compared with smokers or non-smokers. Peptic
ulcer, reflux/heartburn and depression requiring treatment
had a higher prevalence in COPD subjects than in non-
smoking subjects. Anemia was more common in non-
smokers than in COPD subjects. Cardiovascular comorbid-
ities including hypertension, heart attack, heart failure,
arrhythmia, and stroke and heart trouble were all more
common in COPD subjects than smokers or non-smokers;
however, the differences in angina, stroke, arrhythmia,
1380 J. Miller et al.and treated hypertension were not significant after
adjusting for age and gender (Fig. 2).
Figs. 3 and 4 show that the proportion of patients with
most of the comorbidities did not change significantly with
increasing severity of airflow limitation (GOLD stage)
except for osteoporosis, inflammatory bowel disease which
were greater in GOLD Stage IV compared with GOLD Stage
III, and anxiety/panic attacks which was more common in
GOLD Stage IV compared with GOLD stage III, hypertension
and angina were more common in GOLD stage II subjects
compared with subjects with GOLD Stage IV.Figure 4 Percentage of COPD subjects with cardiovascular
comorbitities by GOLD stage of disease e þp < 0.05,
þþp < 0.01 GOLD II vs GOLD IV (p values adjusted for age,
gender and smoking).Clinical characteristics of comorbidities in COPD
Table 2 compares the clinical, physiological, imaging, and
inflammatory marker data in COPD subjects at baseline
according to the presence/absence of heart trouble, hy-
pertension, osteoporosis, or diabetes. In general, patients
with any of these four comorbidities tended to be older, be
more breathless, and have a lower exercise capacity, even
after accounting for differences in age, gender, and
smoking pack year history. Despite some statistically sig-
nificant differences, overall the severity of airflow limita-
tion was largely independent of the presence of these
comorbidities (Table 2). Patients with heart trouble, dia-
betes and hypertension had higher BMI and FFMI than those
without these comorbidities, whereas patients with osteo-
porosis had lower BMI and FFMI.
The extent of low attenuation areas in the lungs
(emphysema as measured by %LAA) was less in those pa-
tients with heart trouble, hypertension, and diabetes, but
greater in patients with osteoporosis than in those without
these comorbidities (Table 2).
COPD subjects with heart trouble, hypertension, and
diabetes had elevated serum levels of fibrinogen, CRP, IL-6,
IL-8, CCL-18, CC16 and CRP; however, only fibrinogen, IL-6,
IL-8 in those with heart trouble, and fibrinogen in those
with hypertension remained significantly different after
adjustment for age, gender, and smoking pack year history
differences.Figure 3 Percentage of COPD subjects with general comor-
bidities by GOLD stage of disease #p < 0.05 GOLD GOLD III Vs
GOLD IV (p values adjusted for age, gender and smoking).Effect of comorbidities on outcomes in COPD
The effect of comorbidity on mortality in COPD was
assessed over a 1060-day follow-up period adjusted for age,
gender, and smoking pack year history. When co-existing
with COPD, heart trouble (HR 1.5, 95% CI 1.1e2.0), heart
failure (HR 1.9, 95% CI 1.3e2.9), ischemic heart disease (HR
1.5, 95% CI 1.1e2.0), heart disease (HR 1.5, 95% CI
1.2e2.0), and diabetes (HR 1.7, 95% CI 1.2e2.4) were all
associated with significantly increased mortality. Neither of
the hazard ratios associated with hypertension and osteo-
porosis, for mortality in COPD patients, were significantly
different from unity. Fig. 5 presents the survival curves in
COPD patients with or without heart trouble, hypertension,
osteoporosis or diabetes using a Cox proportional hazard
model, adjusting the data for age, gender and smoking pack
year history. In this analysis the survival for COPD subjects
with heart trouble or diabetes was worse than those
without these comorbidities.
The number of comorbidities was also associated with
increased mortality (Table 3). The hazard ratio for mor-
tality for each additional comorbidity was 1.2 (95%CI
1.1e1.4). The presence of any of these comorbidities was
not associated with decline in FEV1, change in SGRQ,
change in BODE index, or change in BMI, nor with exacer-
bation frequency (Table 2).
Discussion
This study shows that COPD is associated with increased
comorbidities compared with smoker or nonsmoker sub-
jects with normal lung function after adjusting for age and
gender. Comorbidity was generally not associated with the
severity of the airflow limitation (GOLD stage). Cardiovas-
cular comorbidity and diabetes were associated with
increased mortality and higher levels for some markers of
systemic inflammation. The cumulative number of comor-
bidities was significantly associated with increased
Table 2 Comparison of the pattern of clinical, physiological, imaging and inflammatory data in COPD patients at baseline, and
relevant outcomes at 3-year follow-up, according to the presence or absence of self-reported heart trouble, hypertension,
osteoporosis or diabetes at recruitment into ECLIPSE. Data are presented as mean  SD, median  IQR (for biomarkers) or
frequency (percentage), and a color code is used to highlight differences and similarities between patterns (red Z worse;
green Z better; white Z neutral). For further explanations, see text. ⱡ p values are form a Cox proportional hazards model.
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management of the COPD population.The type and proportion of COPD patients with
comorbidities
Our findings are in agreement with recent studies showing
that cardiovascular disease, diabetes, osteoporosis,
gastroesophageal reflux and anxiety/panic are more com-
mon in the COPD population compared with healthy con-
trols.11,12 Whereas subjects with heart trouble,
hypertension and diabetes had higher BMI and less
emphysema, those with osteoporosis had lower BMI and
more emphysema. All of these comorbidities wereassociated with increased breathlessness and reduced
6 min walking distance.Comorbidity and mortality
Cardiovascular comorbidity and diabetes were associated
with increased mortality in this COPD cohort after adjusting
for age, gender, and smoking pack year history. The cu-
mulative number of comorbidities was also associated with
increased mortality. An association with increasing numbers
of comorbidities and mortality has been reported in larger
population studies.12 Targeted treatment of comorbidities
in the COPD population may therefore have an impact on
outcome.
Figure 5 Survival curves in COPD with or without heart trouble, hypertension, osteoporosis or diabetes using a Cox proportional
hazard model, adjusting the data for age, gender and smoking pack year history.
1382 J. Miller et al.Inflammation and comorbidity
COPD patients with cardiovascular comorbidity had an
increased level of systemic inflammatory markers
compared with control subjects. Circulating fibrinogen was
significantly increased in these comorbid conditions. IL-6,
IL-8, fibrinogen and CCL-18 were also increased in COPD
patients with heart trouble, hypertension, and diabetes,
though not always significantly. A number of other inflam-
matory markers were altered in each of the comorbidities:
hypertension was associated with increased plasma fibrin-
ogen and diabetes was associated with higher plasma CRP.
Increased systemic inflammation in COPD patients with
cardiac comorbidities supports the hypothesis of systemic
inflammation as a potential mechanistic link between COPD
and these comorbidities. Mechanisms linking COPD with its
associated comorbidities have begun to be investigated,
particularly in the case of cardiovascular disease. FactorsTable 3 Cumulative effect of comorbidity mortality in COPD us
smoking.
Number of
comorbidities
Number (%) of subjects with different
number of comorbidities
1 1023 (37%)
2 902 (32%)
3 551 (20%)
4þ 211 (8%)such as systemic inflammation, oxidative stress, and arte-
rial stiffness have been reported.25e28
From our data, fibrinogen was increased in COPD pa-
tients in association with each of the cardiovascular
comorbidities that had an impact on mortality. Elevated
plasma fibrinogen has been associated with increased hos-
pitalization rates and mortality in COPD29 and is known to
be inversely associated with FEV1
30 and the rate of decline
in FEV1 in one previous study,
31 but not in this cohort.32 It is
interesting that C-reactive protein, which is a strong inde-
pendent predictor of hospitalization and death in COPD,
independent of FEV1 and smoking history,
33,34 was associ-
ated with diabetes, but not with heart disease or hyper-
tension. It may be that CRP and comorbidities provide
complementary prognostic information in COPD.
Comorbidities should be considered as potential con-
founding factors in studies of inflammation in COPD. In-
flammatory conditions such as inflammatory bowel diseaseing a logistic regression model adjusting for age, gender and
Number of
comorbidities
Odds ratio (95% confidence
interval)
p Value
1 vs 0 1.74 (1.182e2.56) 0.005
2 vs 0 1.73 (1.131 2.64) 0.011
3 vs 0 2.00 (1.117) 0.011
4þ vs 0 4.57 (2.30) <0.001
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in COPD studies, but not so diabetes or heart disease,35 and
yet these conditions are also associatedwith increased levels
of inflammatory mediators common to COPD. Excluding
these common comorbidities would make trial results less
applicable to the COPD population as a whole.Limitations
The COPD patients in this study comprised GOLD stage
IIeIV, excluding the mildest category. Thus it is therefore
not possible to extrapolate results to patients with mild
COPD.
Although this study investigated a large cohort of COPD
patients and healthy subjects, the numbers of patients in
some sub-categories were still small, which may limit the
ability to generalize some of the findings. The cohorts were
not ideally matched for age and smoking history although
we have adjusted for these factors in the analysis.
Comorbidities were assessed by patient recall which
limits the accuracy of the recorded comorbidities.
The cohort was a convenience sample of COPD pa-
tients recruited from primary and secondary care of
largely moderate to severe patients with COPD. As such
these patients may be more likely to have more comor-
bidity although we found no relationship between
numbers of comorbidities and the severity of the airflow
limitation.
A further limitation in our study is that smoking status
was assessed by subject recall which is subject to bias and
could result in differences in reported smoking in the
different groups, which could have resulted in residual
confounding by smoking in the analysis.
Finally, ECLIPSE was an observational study in which
subjects were treated as deemed best by their clinicians.
The degree by which treatment for COPD or for comorbid
conditions or the duration of the disease may have influ-
enced outcome cannot be determined from the current
data set. In addition other factors such as social class and
alcohol consumption could have influenced the results.
However, the strength of this study was the in-depth
characterization of the COPD population.Conclusions
Comorbidities are common in COPD patients and, when
present, are associated with poor clinical outcomes and
increased mortality. In particular, cardiovascular disease
and diabetes are associated with a poor clinical outcome in
COPD patients. Comorbidities associated with increased
mortality are associated with increased systemic inflam-
mation. Increased numbers of comorbidities have a detri-
mental effect on outcome in COPD.Conflict of interest
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